Figure 1. Relative Hazard of Major Bleeding Comparing Patients With Oral Anticoagulation Taking Aspirin With Patients Not Taking Aspirin by Estimated 1-Year Risk According to the ABC (Age, Biomarkers, and Clinical History)–Bleeding Risk Score.

Graphs show relative hazards (lines) and 95% CIs (shaded areas) for the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) (A) and RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) (B) cohorts. The bottom of each panel shows the distribution of the patients with ABC-bleeding risk scores as a density plot for each group at baseline.